The Anti-Fungal
Treatment Market Overview and Analysis by
Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines),
Therapeutic Indication (Systemic, Candidiasis, Cryptococcosis, Prophylactic Use
of Antifungals, Coccidioidomycosis), Pathogen (Candid, Aspergillus,
Cryptococcus, CoccidiodiesImmitis, Zygomycetes, Trichophyton), End Users
(Hospitals & Clinics, Dermatology Clinics) and Region (Americas, Europe,
Asia-Pacific, and Middle East & Africa) - Forecast till 2032
The global antifungal treatment market has
been assessed to grow significantly over the forecast period owing to
influential factors such as the increase in the prevalence of fungal infections
such as athlete's foot, ringworm infection, severe systemic infections, and
others, which has driven the demand and availability of their treatment.
The global anti-fungal treatment market is
projected to reach USD 18.9 Billion by 2030 at a 6.1% CAGR during the forecast
period of 2023 to 2032.
Rising prevalence of immunological disease
and availability of a wide range of treatment products have increased the
growth of the global market for antifungal treatment. additionally, growing
awareness about the side effects of conventional drugs and the availability of
improved drugs support the growth of the market.
The global antifungal treatment
market was growing moderately and expected to grow at the same pace over the
forecast period 2017 to 2023. An increase in the patient population and
geriatric population prone to fungal diseases and the growing prevalence of HIV
virus infections are essential factors influencing the market growth of the
global antifungal treatment market.
Segmental analysis
The global antifungal treatment market size is segmented based on drug
class, therapeutic indication, pathogen, end user, and region.
On the basis of drug class, the antifungal
treatment market has been segmented into allylamines, azoles, echinocandins,
polyenes, pyrimidines, and others.
Based
on therapeutic indication, the market has been segmented into candidiasis,
coccidioidomycosis, cryptococcosis, and systemic. The systemic segment has been assessed to grow at the highest CAGR and
accounted for the largest market share over the forecast period.
On the basis of the pathogen, the market is
segmented into candida, Aspergillus, coccidioides immitis, Cryptococcus,
Trichophyton, zygomycetes, and others.
On the basis of the end user, the market
has been segmented into dermatology clinics, hospitals & clinics, and other
users.
Based on region, the global antifungal
treatment market has been segmented into North America, Europe, Asia Pacific,
and the Middle East and Africa.
Key Players
the key players in the global antifungal
treatment market are Pfizer Inc. (U.S), Merck & Co., Inc. (U.S), Sanofi
(France), Novartis AG (Switzerland), Bayer AG (Germany), and Astellas (Japan).
Regional Analysis
North America has been accounted for the
largest region in the global antifungal treatment market over the forecast
period, owing to the growing occurrence of immunological diseases and
increasing healthcare expenditure by the governments.
Europe has been assessed as the second
major market and holds a significant market share in the global antifungal
treatment market. The European market for antifungal treatments is projected to
grow extensively through the forecast period, owing to the accessibility of
advanced treatment facilities, skilled medical experts, and the adoption of new
therapies for antifungal treatments.
Asia Pacific region has been assessed as
the fastest growing region of the global antifungal treatment market, owing to
the alarmingly high prevalence of HIV diseases in this region. Additionally,
the increasing awareness about antifungal treatment methods and availability of
advanced treatment techniques has been expected to drive the market in the Asia
Pacific region over the forecast period. In the Asia Pacific region, the market
has been assessed to witness lucrative opportunities in emerging economies such
as China and India, with China leading the market growth with a CAGR of 5.24%
by 2023.
The Middle East & Africa has been
projected to show moderate growth over the forecast period, due to significant
factors such as lack of awareness concerning the anti-fungal treatment, limited
access and availability of basic healthcare treatment facilities, and low
income of consumers,
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting
Services. MRFR team have supreme objective to provide the optimum quality
market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research
and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
0 Comments